Recalls & Warnings December 08, 2017 Limbrel Capsules for Osteoarthritis Linked With Potentially Life-Threatening Health Risk, FDA Warns On December 4, 2017, the FDA urged consumers not to take Limbrel (Primus Pharmaceuticals), a capsule marketed to manage the metabolic processes associated with osteoarthritis, because it has been associated with serious adverse events, including drug-induced liver injury and a lung
Glutathione metabolism reactions can be categorized into glutathione conjugation, glucuronidation, methylation, or detoxification of reactive oxygen species
Research has shown that this decline is due to both intrinsic aging processes and environmental factors like UV exposure and pollution (Shuster et al., 2005)
Sandborn WJ, Feagan BG, Rutgeerts P, Hanauer S, Colombel JF, Sands BE, et al
Oteri V, Galeano F, Panebianco S, Piticchio T, Le Moli R, Frittitta L, et al